Toth Financial Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.98K | Sell |
87
-86
| -50% | -$4.71K | ﹤0.01% | 658 |
|
|
2026
Q1 | $9.77K | Sell |
173
-32
| -16% | -$1.87K | ﹤0.01% | 562 |
|
|
2025
Q4 | $12.2K | Hold |
205
| – | – | ﹤0.01% | 528 |
|
|
2025
Q3 | $11.1K | Hold |
205
| – | – | ﹤0.01% | 528 |
|
|
2025
Q2 | $11.3K | Sell |
205
-5,900
| -97% | -$347K | ﹤0.01% | 479 |
|
|
2025
Q1 | $432K | Buy |
6,105
+5,900
| +2,878% | +$397K | 0.05% | 164 |
|
|
2024
Q4 | $13.5K | Hold |
205
| – | – | ﹤0.01% | 434 |
|
|
2024
Q3 | $14.4K | Hold |
205
| – | – | ﹤0.01% | 419 |
|
|
2024
Q2 | $16.9K | Hold |
205
| – | – | ﹤0.01% | 411 |
|
|
2024
Q1 | $17.9K | Hold |
205
| – | – | ﹤0.01% | 395 |
|
|
2023
Q4 | $19.8K | Hold |
205
| – | – | ﹤0.01% | 392 |
|
|
2023
Q3 | $18.1K | Hold |
205
| – | – | ﹤0.01% | 382 |
|
|
2023
Q2 | $17.8K | Hold |
205
| – | – | ﹤0.01% | 405 |
|
|
2023
Q1 | $19.9K | Hold |
205
| – | – | ﹤0.01% | 385 |
|
|
2022
Q4 | $21.2K | Hold |
205
| – | – | ﹤0.01% | 373 |
|
|
2022
Q3 | $17K | Sell |
205
-95
| -32% | -$8.46K | ﹤0.01% | 390 |
|
|
2022
Q2 | $25K | Sell |
300
-20
| -6% | -$1.59K | ﹤0.01% | 342 |
|
|
2022
Q1 | $25K | Hold |
320
| – | – | ﹤0.01% | 358 |
|
|
2021
Q4 | $28K | Hold |
320
| – | – | ﹤0.01% | 351 |
|
|
2021
Q3 | $25K | Hold |
320
| – | – | ﹤0.01% | 366 |
|
|
2021
Q2 | $27K | Hold |
320
| – | – | ﹤0.01% | 338 |
|
|
2021
Q1 | $24K | Hold |
320
| – | – | ﹤0.01% | 358 |
|
|
2020
Q4 | $28K | Hold |
320
| – | – | ﹤0.01% | 300 |
|
|
2020
Q3 | $24K | Hold |
320
| – | – | ﹤0.01% | 291 |
|
|
2020
Q2 | $39K | Hold |
320
| – | – | 0.01% | 238 |
|
|
2020
Q1 | $27K | Buy |
320
+20
| +7% | +$1.72K | 0.01% | 214 |
|
|
2019
Q4 | $25K | Hold |
300
| – | – | 0.01% | 243 |
|
|
2019
Q3 | $20K | Hold |
300
| – | – | ﹤0.01% | 275 |
|
|
2019
Q2 | $26K | Hold |
300
| – | – | 0.01% | 255 |
|
|
2019
Q1 | $27K | Sell |
300
-100
| -25% | -$9.27K | 0.01% | 240 |
|
|
2018
Q4 | $34K | Hold |
400
| – | – | 0.01% | 208 |
|
|
2018
Q3 | $39K | Hold |
400
| – | – | 0.01% | 216 |
|
|
2018
Q2 | $38K | Hold |
400
| – | – | 0.01% | 222 |
|
|
2018
Q1 | $32K | Hold |
400
| – | – | 0.01% | 230 |
|
|
2017
Q4 | $36K | Buy |
+400
| New | +$34.8K | 0.01% | 230 |
|
Other funds holding BMRN
VPC
Toth Financial Advisory's BMRN Position: Q2 2026 in Review
Toth Financial Advisory reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q2 2026, selling an estimated $4.71K and leaving 87 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #658.
Toth Financial Advisory first reported a position in BMRN in Q4 2017 and has held it in 35 quarters since. The position peaked at $432K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Toth Financial Advisory held 87 shares of BioMarin Pharmaceuticals worth $4.98K as of Q2 2026.
- Toth Financial Advisory sold 86 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Toth Financial Advisory's portfolio in Q2 2026, its #658 holding.
- Toth Financial Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Toth Financial Advisory's BioMarin Pharmaceuticals position peaked at $432K in Q1 2025.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.